



## PRESS RELEASE

Leipzig, January 24, 2005

### **„Just married: *in vitro* and *in silico*” – innovative strategy for ADME optimised compounds” – the new service of NIMBUS Biotechnology**

„Just married: *in vitro* and *in silico* “ - the new slogan of NIMBUS Biotechnology, a privately-owned biotech company from Leipzig (Germany), of their innovative new service department. It provides a maximum of information for an initially compound ranking and supports your decisions at all stages of drug discovery.

NIMBUS Biotechnology, known as a leading provider for innovative *in vitro* early ADME assays, based their service measurements on the well known TRANSIL<sup>®</sup> technology. Those bead-based assays allow for the rapid and easy determination of the important physicochemical parameters lipophilicity (characterizing intestinal absorption) and protein binding (mainly responsible for drug distribution) in 384/96 well high-throughput format. Using the high quality data of the *in vitro* assays along with the reliable and versatile ADME prediction tool PK-Map<sup>™</sup> lead to important ADME parameters like organ/plasma partitioning and volume of distribution.

Wolfgang Lerch, CEO of NIMBUS Biotechnology, pointed out: “Pressure of competition and the expectations of shareholders, forces pharmaceutical companies to assess “drug-like” properties earlier and in a smarter fashion than ever before. Therefore NIMBUS Biotechnology is proud to provide this unique combination of *in vitro* assays and *in silico* prediction now for a wide range of companies, not capable to access all ADME parameters by their own. For this purpose we did extend our service department up to a throughput of 1000 compounds per day.”

Over the next few years the degree of automation for ADME issues will continue to increase and fully automated high-throughput *in vitro* assays will be used alongside *in silico* modelling and data interpretation. The overwhelming benefits of this strategy, like accelerating drug discovery by ranking promising compounds and sorting out compounds with adverse ADME behaviour will help to save time and money by higher success rates.

For further information please contact:

NIMBUS Biotechnologie GmbH  
Dr. Thomas Löffler  
Sales and Scientific Support  
Eilenburger Str. 4, 04317 Leipzig  
Germany  
Phone +49-341-4793 350  
[tloeffler@nimbus-biotech.com](mailto:tloeffler@nimbus-biotech.com)  
[www.nimbus-biotechnology.com](http://www.nimbus-biotechnology.com)

The logo for NIMBUS Biotechnology features a stylized red 'N' with a white dot inside, followed by the word "NIMBUS" in blue. Below it, the word "Biotechnology" is written in a smaller blue font, and the tagline "Modern tools for drug discovery" is written in a smaller black font.

**NIMBUS**  
Biotechnology  
Modern tools for drug discovery